Table 2– Concomitant medication use at baseline in patients completing 12 weeks of riociguat treatment
CTEPHPAHTotal
Subjects413172
Any medication41 (100.0)30 (96.8)71 (98.6)
PAH-specific medication
 Any medication4 (9.8)2 (6.5)6 (8.3)
 Bosentan4 (9.8)2 (6.5)6 (8.3)
Calcium channel blockers
 Any medication6 (14.6)8 (25.8)14 (19.4)
 Amlodipine4 (9.8)3 (9.7)7 (9.7)
 Diltiazem0 (0.0)1 (3.2)1 (1.4)
 Felodipine0 (0.0)1 (3.2)1 (1.4)
 Lercanidipine0 (0.0)1 (3.2)1 (1.4)
 Nifedipine1 (2.4)0 (0.0)1 (1.4)
 Nitrendipine1 (2.4)0 (0.0)1 (1.4)
 Verapamil0 (0.0)2 (6.5)2 (2.8)
Diuretics
 Any medication31 (75.6)26 (83.9)57 (79.2)
 Furosemide7 (17.1)4 (12.9)11 (15.3)
 Furosemide plus spironolactone1 (2.4)1 (3.2)2 (2.8)
 Hydrochlorothiazide6 (14.6)11 (35.5)17 (23.6)
 Piretanide1 (2.4)0 (0.0)1 (1.4)
 Spironolactone15 (36.6)10 (32.3)25 (34.7)
 Torasemide16 (39.0)16 (51.6)32 (44.4)
 Xipamide3 (7.3)4 (12.9)7 (9.7)
Oral anticoagulants
 Any medication38 (92.7)22 (71.0)60 (83.3)
 Phenprocoumone38 (92.7)22 (71.0)60 (83.3)
Oxygen
 Any medication12 (29.3)7 (22.6)19 (26.4)
 Oxygen12 (29.3)7 (22.6)19 (26.4)
  • Data are presented as n or n (%). CTEPH: chronic thromboembolic pulmonary hypertension; PAH: pulmonary arterial hypertension.